ReviewTurkish thoracic journal2019
Angiotensin-Converting Enzyme Inhibitors Induce Cough.
Review in Turkish thoracic journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2023Pooled it
- Telmisartan reduces systemic inflammation and alters the renin-angiotensin system in mild COVID-19.Scientific reports · 2025Trial
- Sex differences in cardiovascular‑kidney‑metabolic syndrome: From pathogenesis to treatment response (Review).International journal of molecular medicine · 2026Review
- Prevalence and risk factors for refractory and untreated chronic cough in the Canadian Longitudinal Study of Aging.ERJ open research · 2026Article
- A comprehensive study on drug-related dysphonia: a 20-year disproportionality analysis of the FAERS database.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- A Retrospective Application of Deep Sternal Wound Dehiscence and Malunion Risk Scores on Sternal Nonunion Patients.Plastic and reconstructive surgery. Global open · 2025Article
- Targeting Kinin B1R Attenuates Hypertension Through AT1R-Dependent Mechanisms.Circulation research · 2025Article
- The efficacy and safety of left bundle branch pacing combined with sacubitril/valsartan or enalapril in the treatment of elderly coronary heart disease with chronic heart failure.Pakistan journal of medical sciences · 2025Article
- WAO - ARIA consensus on chronic cough: Executive summary.The World Allergy Organization journal · 2025Review
- Molecular basis of human angiotensin-1 converting enzyme inhibition by a series of diprolyl-derived compounds.The FEBS journal · 2025Article
- Pharmacogenomic biomarkers of ACE inhibitor-induced cough in a multi-ethnic UAE cohort.Frontiers in pharmacology · 2025Article
- Cross talk on therapeutic strategies: natriuretic peptides and inhibiting neprilysin in hypertension management.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Review
- The pharmaco-epigenetics of hypertension: a focus on microRNA.Molecular and cellular biochemistry · 2024Review
- Molecular insights into the inhibition of angiotensin-converting enzyme 1 by hemopressin peptides.Scientific reports · 2024Article
- Considering Adverse Effects of Common Antihypertensive Medications in the ED.Current hypertension reports · 2024Review
- ACE inhibitors and their interaction with systems and molecules involved in metabolism.Heliyon · 2024Review
- Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?Life (Basel, Switzerland) · 2023Review
- Is It Still Relevant to Discover New ACE Inhibitors from Natural Products? YES, but Only with Comprehensive Approaches to Address the Patients' Real Problems: Chronic Dry Cough and Angioedema.Molecules (Basel, Switzerland) · 2023Review
- Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions.British journal of clinical pharmacology · 2022Article
- Bioactive Peptides Obtained from Legume Seeds as New Compounds in Metabolic Syndrome Prevention and Diet Therapy.Foods (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiotensin-converting enzyme inhibitors (ACE-I) are widely used in diseases, such as hypertension, congestive heart failure, and myocardial infarction. Although these drugs are well tolerated, one out of five patients discontinues ACE-I due to drug side effects, mainly chronic cough. However, the pathogenesis of ACE-I-induced cough remains controversial and requires further study. In this review, the mechanisms that are suggested in ACE-I-induced cough pathophysiology will be discussed in detail in light of the current literature.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.